BioNTech and Bristol Myers Squibb Report Encouraging Phase 2 Data for Pumitamig in Advanced NSCLC

BioNTech and Bristol Myers Squibb reported initial Phase 2 ROSETTA Lung-107 results for pumitamig plus docetaxel in metastatic NSCLC that progressed after first-line immunotherapy and chemotherapy. The combination achieved a confirmed objective response rate of 36.7% and median progression-free survival of 6.9 months, with a manageable safety profile and no new safety signals. The companies said the findings support continued development of pumitamig; the article did not report financial results or stock-price movements.